全文获取类型
收费全文 | 130513篇 |
免费 | 9519篇 |
国内免费 | 5281篇 |
专业分类
耳鼻咽喉 | 619篇 |
儿科学 | 2418篇 |
妇产科学 | 1335篇 |
基础医学 | 20139篇 |
口腔科学 | 2226篇 |
临床医学 | 9987篇 |
内科学 | 21398篇 |
皮肤病学 | 1981篇 |
神经病学 | 12530篇 |
特种医学 | 2036篇 |
外国民族医学 | 20篇 |
外科学 | 8873篇 |
综合类 | 19031篇 |
现状与发展 | 24篇 |
预防医学 | 7112篇 |
眼科学 | 1517篇 |
药学 | 20282篇 |
15篇 | |
中国医学 | 4377篇 |
肿瘤学 | 9393篇 |
出版年
2024年 | 173篇 |
2023年 | 1752篇 |
2022年 | 2732篇 |
2021年 | 5014篇 |
2020年 | 4000篇 |
2019年 | 4070篇 |
2018年 | 3860篇 |
2017年 | 3991篇 |
2016年 | 3997篇 |
2015年 | 4520篇 |
2014年 | 7438篇 |
2013年 | 8606篇 |
2012年 | 7636篇 |
2011年 | 8689篇 |
2010年 | 7065篇 |
2009年 | 6836篇 |
2008年 | 7099篇 |
2007年 | 6775篇 |
2006年 | 6095篇 |
2005年 | 5544篇 |
2004年 | 4803篇 |
2003年 | 4147篇 |
2002年 | 3143篇 |
2001年 | 2656篇 |
2000年 | 2479篇 |
1999年 | 2099篇 |
1998年 | 2018篇 |
1997年 | 1834篇 |
1996年 | 1591篇 |
1995年 | 1331篇 |
1994年 | 1204篇 |
1993年 | 1090篇 |
1992年 | 965篇 |
1991年 | 891篇 |
1990年 | 740篇 |
1989年 | 640篇 |
1988年 | 566篇 |
1987年 | 552篇 |
1986年 | 498篇 |
1985年 | 883篇 |
1984年 | 931篇 |
1983年 | 619篇 |
1982年 | 706篇 |
1981年 | 615篇 |
1980年 | 523篇 |
1979年 | 436篇 |
1978年 | 369篇 |
1977年 | 262篇 |
1976年 | 236篇 |
1975年 | 191篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
目的探讨对先天性耳甲腔型小耳畸形患者行全扩张法全耳再造术后,利用残耳皮瓣改善再造耳颅耳沟的效果。方法回顾分析 2012 年 1 月—2017 年 1 月收治的 150 例先天性耳甲腔型小耳畸形患者。其中男 92 例,女 58 例;年龄 6.5~35.0 岁,平均 11.1 岁。采用一期扩张器埋置、二期全扩张法全耳再造术后发现上部颅耳沟浅显;于 6~12 个月后行三期再造耳修整。将残耳垂通过“Z”字改型转移以再造耳垂。在残耳上部作蒂在轮屏切迹的残耳上部皮瓣,弧形切开松解并加深上部颅耳沟,将上部残耳皮瓣向颅耳沟创面旋转推进缝合以覆盖创面;将带皮下组织蒂的残耳软骨组织瓣插入支架底部形成的腔隙内,并缝合固定,以增加支架的高度;耳甲腔区其余残耳皮瓣用以覆盖耳甲腔创面。结果术后拆线时 1 例患儿皮瓣远端出现直径约 0.5 cm 的表皮水疱,经换药 2 周后愈合;其余患者皮瓣成活良好。患者均获随访,随访时间 6~12 个月,平均 9.6 个月。再造耳上部颅耳沟均明显加深,再造耳支架高度不同程度增加,双耳对称性佳,耳甲腔无明显挛缩变小,再造耳外观满意。再造耳上部表面毛发明显减少,耳周发际线上移。结论采用耳甲腔型小耳畸形的残耳皮瓣及残耳软骨瓣转移,不仅可加深颅耳沟,而且可增加上部支架的高度,术后颅耳沟变形较轻,再造耳与正常耳廓的对称性更佳。 相似文献
53.
目的:观察PERK蛋白对结肠癌细胞药物敏感性的影响,并进一步探讨其相关作用机制。方法:结肠癌细胞系HCT116分为三组:空白对照(Control)组、下调PERK表达(si-PERK)组、阴性对照(si-NC)组;采用免疫荧光及RT-PCR验证转染效率;利用CCK-8实验检测下调PERK表达后结肠癌细胞对化疗药物5-FU的敏感性变化;Annexin V-FITC凋亡实验检测下调PERK表达对结肠癌细胞凋亡的影响;利用RT-PCR及Western Blot实验检测PERK信号通路中关键分子eIF2α、ATF4、CHOP、XIAP的mRNA及蛋白表达变化。结果:RT-PCR实验表明:与正常对照组相比,si-PERK 组mRNA的表达显著下降(P<0.05),免疫荧光提示转染效率达80%以上;CCK-8实验发现与si-NC组相比,5-FU对 si-PERK组细胞的半数抑制浓度(IC50)明显降低(P<0.01);Annexin V-FITC凋亡实验发现与si-NC组相比,si-PERK组细胞的凋亡发生率显著升高(P<0.05);RT-PCR及Western Blot实验发现与si-NC组相比,si-PERK组细胞中PERK信号通路下游关键分子eIF2α、ATF4、CHOP的mRNA及蛋白表达均明显降低(P<0.05)。结论:在结肠癌细胞中,抑制PERK表达后,其可能通过下调eIF2α、ATF4、CHOP的表达促进细胞发生凋亡,从而促进细胞对化疗药物5-FU的敏感性。 相似文献
54.
55.
《Vaccine》2021,39(26):3498-3508
Adenovirus infections are a major cause of epidemic keratoconjunctivitis (EKC), which can lead to corneal subepithelial infiltrates and multifocal corneal opacity. In the current study, we investigated the use of an E1/E3-deleted adenovirus serotype 5 (Ad5) vector as a vaccine administered intramuscularly (IM) or intranasally (IN) against subsequent challenges with a luciferase-expressing Ad5 (Ad5-Luci) vector via eyedrop. We evaluated the adaptive immune response to Ad5 vector vaccination and confirmed a robust polyfunctional CD8 T cell response in splenic cells. Neutralizing Ad5 antibodies were also measured in the sera of vaccinated mice as well as Ad5 antibody in the eye wash solutions. Upon challenge with Ad5-Luci vector 8 weeks post the primary immunization, transduction was significantly reduced by > 70% in the vaccinated mice, which was slightly better in IM- vs. that in IN-vaccinated animals. Resistance to subsequent challenge was observed 10 months post primary IM vaccination, with sustained reduction up to 60% in the Ad5-Luci vector transduction. Passive immunization of naive mice with antisera from IM to vaccinated mice subsequently challenged with the Ad5-Luci vector resulted in approximately 40% loss in transduction efficiency. Furthermore, the mice that received IM immunization with or without CD8 T cell depletion showed > 40% and 70% reductions, respectively, in Ad8 genomic copies after Ad8 topical challenge. We conclude that Ad-vector vaccination successfully induced an adaptive immune response that prevented subsequent Ad transduction in the cornea and conjunctiva-associated tissues in a mouse model of adenovirus keratoconjunctivitis, and that both cellular and humoral immunity play an important role in preventing Ad transduction. 相似文献
56.
《International journal of oral and maxillofacial surgery》2020,49(8):984-992
The objectives of this study were to evaluate survival in 141 patients with stage II–IV oral squamous cell carcinoma (OSCC) treated with preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil (IADCPIVF) via the superficial temporal artery, and to clarify the prognostic factors. The study population included 59 patients with stage II OSCC, 34 with stage III, and 48 with stage IV. After IADCPIVF, 139 patients underwent surgery; minimally invasive surgeries (MIS) including excisional biopsy were performed on 96 patients with a remarkably good response to IADCPIVF. The primary tumour response rate was 99.3% (complete response rate 56.7%, good partial response rate 17.0%, fair partial response rate 25.5%). Additionally, there were no serious adverse events associated with IADCPIVF. The 5-year overall survival rate was 74.6% (stage II 83.6%, stage III 72.7%, stage IV 64.8%). In the multivariate analysis of survival, T classification and clinical tumour response were significant prognostic factors. Eight (8.3%) of the patients who received MIS had primary recurrence and six were salvaged. In conclusion, IADCPIVF is safe and efficacious for treating OSCC, and MIS could reduce the extent of primary tumour resection in the case of a remarkably good response. 相似文献
57.
目的:探讨微小RNA-942-5p(miR-942-5p)在肝细胞癌(HCC)组织中的表达及其功能。方法:用实时定量PCR检测西安交通大学第一附属医院样本库保存的73例HCC组织和对应癌旁组织中miR-942-5p的表达。分析miR-942-5p表达与HCC患者临床病理资料的关系,同时分析TCGA数据库中miR-942-5p表达与HCC患者总生存率的关系。Transwell小室检测干扰miR-942-5p表达后HCC细胞迁移和侵袭能力的变化,StarBase V3.0网站和荧光素酶报告基因质粒预测分析miR-942-5p的下游靶点,并用Western blot验证。结果:miR-942-5p表达量在HCC组织中明显高于对应癌旁组织(2.390 vs. 1.764,P0.05)。miR-942-5p表达量与HCC患者肿瘤数目、血管浸润和临床分期明显有关(均P0.05)。miR-942-5p高表达HCC患者总生存率明显低于miR-942-5p低表达HCC患者(19.535%vs. 53.873%,P0.05)。沉默miR-942-5p表达后,肝癌HCCLM3和MHCC97H细胞迁移和侵袭能力明显减弱(均P0.05)。预测与分析结果显示,扣针蛋白5(FBLN5)是miR-942-5p的直接下游靶点(P0.05),沉默miR-942-5p表达导致HCCLM3和MHCC97H细胞中FBLN5表达增加。结论:miR-942-5p在HCC组织中表达异常升高并与恶性临床特征和不良预后密切相关,机制可能与miR-942-5p抑制FBLN5表达促进HCC细胞迁移和侵袭有关。 相似文献
58.
《Vaccine》2021,39(45):6601-6613
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc) in clinical development for the induction and augmentation of neutralizing IgG titers against SARS-CoV-2 viral infection to address the COVID-19 pandemic. The Fc moiety is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcγR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling. AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc moiety and induced comparable long-term neutralizing titers with a single dose vs. two doses. To further enhance immunogenicity, AKS-452 was evaluated in formulations containing a panel of adjuvants in which the water-in-oil adjuvant, Montanide™ ISA 720, enhanced neutralizing IgG titers by approximately 7-fold after one and two doses in mice, including the neutralization of live SARS-CoV-2 virus infection of VERO-E6 cells. Furthermore, ISA 720-adjuvanted AKS-452 was immunogenic in rabbits and non-human primates (NHPs) and protected from infection and clinical symptoms with live SARS-CoV-2 virus in NHPs (USA-WA1/2020 viral strain) and the K18 human ACE2-trangenic (K18-huACE2-Tg) mouse (South African B.1.351 viral variant). These preclinical studies support the initiation of Phase I clinical studies with adjuvanted AKS-452 with the expectation that this room-temperature stable, Fc-fusion subunit vaccine can be rapidly and inexpensively manufactured to provide billions of doses per year especially in regions where the cold-chain is difficult to maintain. 相似文献
59.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献